ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

Greenwald Disagrees With WHT Report But Won’t Fight Decision; Will Ask For Limited Study, With Scope To Be Modified

January 15, 1988

CMS Inserts Unprecedented Conditions Into Medicare Coverage of Lung Screening

November 14, 2014

In Brief: Public Favors stronger Laws Restricting Teen Smoking; Anderson Expands Pediatric Studies

April 26, 1991

FDA to elevate oncology to office level, consolidate most cancer programs. Search planned for oncologist to head new office.

July 23, 2004

NIH Workshop On Animal Care Planned

May 4, 1990

NCI Bypass Budget Request For FY 1982Seeks $1.192 Billion; Would Fund 40% Of Competing R01s

May 23, 1980